心肌肌球蛋白结合蛋白C与肌钙蛋白早期诊断急性心梗的直接比较
本研究在1954例急诊疑似急性心肌梗死患者中比较了心肌肌球蛋白结合蛋白C(cMyC)与高敏及标准灵敏度肌钙蛋白的早期诊断价值。cMyC诊断急性心梗的判别力与高敏肌钙蛋白相当,联合高敏肌钙蛋白T或标准灵敏度肌钙蛋白I可提高AUC,单次血检分类更准确,尤其在症状发作<3小时的患者中改善更明显。
要点
- cMyC诊断急性心梗的AUC与高敏肌钙蛋白T和I相当,优于标准灵敏度肌钙蛋白I。
- cMyC联合高敏肌钙蛋白T或标准灵敏度肌钙蛋白I可提高诊断判别力。
- 症状发作<3小时患者中,cMyC单次血检分类改善幅度大于高敏肌钙蛋白。
核心结论
- cMyC就诊时诊断急性心梗的判别力与高敏肌钙蛋白T和I相当,在早期就诊患者中可能更优。
研究设计与样本
- 前瞻性观察研究,纳入1954例急诊疑似急性心梗患者,就诊时测量cMyC及高敏和标准灵敏度肌钙蛋白。
主要发现
- 最终诊断急性心梗340例(17%),cMyC浓度在急性心梗患者中显著更高(中位数237 ng/L vs 13 ng/L,P<0.001)。
- 诊断急性心梗的AUC:cMyC 0.924,高敏肌钙蛋白T 0.927,高敏肌钙蛋白I 0.922,标准灵敏度肌钙蛋白I 0.909。
- cMyC联合高敏肌钙蛋白T使AUC增至0.931(P<0.0001),联合标准灵敏度肌钙蛋白I使AUC增至0.926(P=0.003)。
- 单次血检分类的净重分类改善:cMyC对比高敏肌钙蛋白T为+0.149,对比高敏肌钙蛋白I为+0.235(P<0.001)。
- 症状发作<3小时患者中,cMyC对比高敏肌钙蛋白T的净重分类改善为+0.256,对比高敏肌钙蛋白I为+0.308(均P<0.001)。
临床怎么用
- cMyC可作为急性心梗早期诊断的辅助或替代标志物,尤其适用于症状发作早期就诊的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early diagnosis of AMI. METHODS: Unselected patients (N=1954) presenting to the emergency department with symptoms suggestive of AMI, concentrations of cMyC, and high-sensitivity (hs) and standard-sensitivity cTn were measured at presentation. The final diagnosis of AMI was independently adjudicated using all available clinical and biochemical information without knowledge of cMyC. The prognostic end point was long-term mortality. RESULTS: Final diagnosis was AMI in 340 patients (17%). Concentrations of cMyC at presentation were significantly higher in those with versus without AMI (median, 237 ng/L versus 13 ng/L, P<0.001). Discriminatory power for AMI, as quantified by the area under the receiver-operating characteristic curve (AUC), was comparable for cMyC (AUC, 0.924), hs-cTnT (AUC, 0.927), and hs-cTnI (AUC, 0.922) and superior to cTnI measured by a contemporary sensitivity assay (AUC, 0.909). The combination of cMyC with hs-cTnT or standard-sensitivity cTnI (but not hs-cTnI) led to an increase in AUC to 0.931 (P<0.0001) and 0.926 (P=0.003), respectively. Use of cMyC more accurately classified patients with a single blood test into rule-out or rule-in categories: Net Reclassification Improvement +0.149 versus hs-cTnT, +0.235 versus hs-cTnI (P<0.001). In early presenters (chest pain <3 h), the improvement in rule-in/rule-out classification with cMyC was larger compared with hs-cTnT (Net Reclassification Improvement +0.256) and hs-cTnI (Net Reclassification Improvement +0.308; both P<0.001). Comparing the C statistics, cMyC was superior to hs-cTnI and standard sensitivity cTnI (P<0.05 for both) and similar to hs-cTnT at predicting death at 3 years. CONCLUSIONS: cMyC at presentation provides discriminatory power comparable to hs-cTnT and hs-cTnI in the diagnosis of AMI and may perform favorably in patients presenting early after symptom onset. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00470587.
引用
- Kaier TE, Twerenbold R, Puelacher C, et al. Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. Circulation. 2017. PMID: 28972002. doi:10.1161/CIRCULATIONAHA.117.028084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。